Meeting
2013 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
Authors
Lee S. Rosen
UCLA Santa Monica Hematology-Oncology, Santa Monica, CA
Lee S. Rosen , Francisco Robert , Daniela Matei , Jonathan Wade Goldman , David S. Mendelson , E. Gabriela Chiorean , Robert Matthew Strother , Ben K. Seon , Delia Alvarez , Bonne J. Adams , Charles P. Theuer , Michael S. Gordon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01332721
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3059)
DOI
10.1200/jco.2013.31.15_suppl.3059
Abstract #
3059
Poster Bd #
16B
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors.
First Author: David S. Mendelson
Poster
2018 ASCO Annual Meeting
A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.
First Author: Dongmei Ji
Poster
2015 Genitourinary Cancers Symposium
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
First Author: Toni K. Choueiri
Poster
2013 ASCO Annual Meeting
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with capecitabine for advanced solid tumors (including patients with progressive or recurrent HER2-negative metastatic breast cancer).
First Author: Ellis Glenn Levine